Literature DB >> 26424311

Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis.

Natsumi Furuta1, Kunihiko Ishizawa, Makoto Shibata, Setsuki Tsukagoshi, Shun Nagamine, Kouki Makioka, Yukio Fujita, Masaki Ikeda, Shunsuke Yoshimura, Masakatsu Motomura, Koichi Okamoto, Yoshio Ikeda.   

Abstract

We herein investigated the clinical features of three patients with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG), which was initially difficult to distinguish from amyotrophic lateral sclerosis (ALS). The patients exhibited dropped head syndrome or dysphagia as initial symptoms. Although their clinical findings were compatible with the revised El Escorial Criteria for ALS, their progression appeared to be more rapid than that of ALS. Both the edrophonium and repetitive nerve stimulation tests yielded negative results, and diurnal fluctuation was not confirmed. The patients were ultimately diagnosed with anti-MuSK antibody-positive MG. We therefore recommend the measurement of anti-MuSK antibodies when encountering such cases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26424311     DOI: 10.2169/internalmedicine.54.4645

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Amyotrophic Lateral Sclerosis and Myasthenia Gravis Overlap Syndrome: A Review of Two Cases and the Associated Literature.

Authors:  Hongfei Tai; Liying Cui; Yuzhou Guan; Mingsheng Liu; Xiaoguang Li; Yan Huang; Jing Yuan; Dongchao Shen; Dawei Li; Feifei Zhai
Journal:  Front Neurol       Date:  2017-05-22       Impact factor: 4.003

Review 3.  Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss.

Authors:  Nishita Singh; Sucharita Ray; Achal Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2018 Jul-Sep       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.